Could GLP-1 weight loss medications like Ozempic become the ‘drug of everything’?

GLP-1 agonists, including semaglutids such as Ozempic and Wogovy and Tirzepatides such as Mounjaro and Zepbound, originally intended to treat diabetes and type 2 obesity.

But in recent months, studies have shown that these popular medications can have many other health benefits.

Some have even claimed that LPG-1 could become the new “drug of everything.”

Mediterranean diet combined with other changes in lifestyle cuts the risk of diabetes

Dr. Angela Fitch, co-founder and Medical Director of Knowwell, a “Inclusive by weight” health company based in Boston, said he would warn against the labeling of any medication as a “drug of everything”, but he agrees that the GLP-1 show promise.

“LPG-1 are currently approved to treat obesity, type 2 diabetes, secondary prevention of cardiovascular disease, associated metabolic fatty liver disease, chronic renal disease in patients with diabetes and sleep apnea,” Digital News told News.

“More research is needed to determine its effectiveness in the treatment of other chronic conditions.”

However, medicines have shown “remarkable promise” in areas such as addiction treatment and the improvement of neurological conditions such as Alzheimer’s, Fitch said.

The DNA test reveals which children have a higher risk of obesity in adulthood.

“They lower blood pressure, lower cholesterol and decrease visceral adiposity,” he said. “They also significantly improve the quality of life of patients. They have many clinical indications today and many more to come.”

The main benefits of LPG-1

Fitch listed the following main benefits of GLP-1 medications.

• Facilitate effective fat loss and maintenance
• Control blood sugar and prevent diabetes in patients at risk
• Lowering blood pressure
• Improvement of lipids (achieving a profile of healthy blood lipids)
• Reduce the risk of heart disease and kidney disease

“These are not comfort. They are the Holy Grail of Modern Medicine.”

Dr. Brett Osborn, a Florida neurosurgeon and longevity expert, believes that the GLP-1 are “here to stay.”

“These medications not only treat obesity, but are already being promised in everything, from cardiovascular diseases to neurodegenerative disease to addiction,” he told News Digital.

“I have said it before, and I will say it again: these are not comfort. They are the Holy Grail of Modern Medicine.”

Potential risks and inconveniences

The most common side effects of GLP-1 drugs are related to gastrointestinal.

Those include nausea, vomiting, diarrhea, constipation and swelling, especially during the initial dose escalation period, according to Fitch.

“These symptoms often improve over time, but they can be limiting for some patients,” he said.

Other more serious, although rare risks include pancreatitis, gallbladder disease and possible renal lesions, particularly if severe dehydration occurs due to vomiting, the expert warned.

“Not all tolerate them well, and we still don’t have a complete mango on long -term side effects.”

Dr. Marc Siegel, News senior medical analyst, previously warned of the side effects of LPG-1.

“Not all tolerate them well, and we still don’t have a complete mango on long -term side effects,” Digital’s News told News at that time.

“I certainly believe that they are useful, and they can think of many situations in which the risks of heart disease, stroke, diabetes and cancer decrease, as well as the need for bariatric surgery, but surely they are not a unique and mostly size size are not first -line therapy.”

Are all LPG-1 the same?

Not all GLP-1 receiver agonists are the same, Fitch warned.

“While everyone acts in the same basic route, their effectiveness, profiles of side effects and cardiovascular benefits can vary significantly,” Digital News told News.

Semaglutida, such as Ozempic and Wegovy, is currently considered the most powerful LPG-1 for both weight loss and glycemic control, Fitch said, with evidence of cardiovascular benefit in people with type 2 diabetes and obesity.

Semaglutida was also approved as a treatment for puree (steatohepatitis associated with metabolic dysfunction, a serious type of fatty liver disease).

Click here to get the News application

“The tirzepatido (Mounjaro, Zepbound) is an agonist GIP/LPG-1 dual and has demonstrated even greater weight loss in trials with a similar side effect profile,” Fitch said.

“Tirzepatide is approved for sleep apnea and undergo clinical trials for other indications.”

Based on his own clinical experience, Osborn reiterated that in many cases, Tirzepatide is a “upper agent.”

“It is a double incredine, which means that it goes to two biochemical paths,” Digital told News. “Therefore, it is not surprising, therefore, for patients who stabilize in a soloñada, zero, often increases weight loss.”

What to know before starting a LPG-1

LPG-1 are not a “magical bullet,” said Fitch, noting that diet, exercise, sleep and behavioral changes are still essential to obtain complete benefits.

“Before taking LPG-1, people should also know that the side effects are common, and constant clinical attention is required and supervision is required to guarantee safety and efficiency,” he advised.

Click here to register in our health newsletter

“It is not something that people simply access through an internet form and they are treated without good, integral and longitudinal attention.”

For chronic conditions such as obesity or type 2 diabetes, Fitch recommends long -term or even indefinite use as the best approach.

“Reducing the dose can become a viable maintenance strategy once a healthy weight is reached, although this approach is still under study,” he said.

“Patients should consult their doctor to determine which course of action is best according to their specific needs.”

For more health articles, visit www.Newsnews.com/health

Any person interested in starting a GLP-1 medication should consult with a doctor to discuss potential benefits and risks.